A series of 4-anilinoquinazoline-triazole-AZT hybrids were designed and synthesized as anticancer agents. Their cytotoxic potential has been evaluated by means of a micro-dilution assay against three human cancer cell lines (KB, epidermoid carcinoma; HepG2, hepatoma carcinoma; SK-Lu-1, non-small lung cancer). The biological results revealed that compounds 4b and 6d showed good anticancer activities against KB, HepG2, and Lu cell lines (IC 50 values ranging from 9 µM to 100 µM). Especially, compounds 4b and 6d exhibited up to 3-fold more potent than reference drugs erlotinib hydrochloride and AZT in term of anti-lung cancer activity.
The search for new anticancer drugs is of utmost interest due to the emergence and reemergence of cancer diseases. Nucleoside analogues have emerged as important therapeutic agents for the treatment of a wide spectrum of pathologies [1] [2] . Among which, 3'-azido-3'-deoxythymidine (AZT, zidovudine) has known as a nucleoside reverse transcriptase inhibitor used for the treatment of HIV infections. AZT has also been exhibited pronounced anticancer activity, especially in combination with other antitumor agents, such as 5-fluorouracil, cisplatin, and paclitaxel [3] [4] [5] . Besides that, quinazoline derivatives, in particular 4-anilinoquinazolines, are of great interest due to their broad spectrum of biological properties such as hypnotic, sedative, analgesic, anticonvulsant, antiinflammatory, and most importantly, anticancer activities that makes them widely used as a privileged structure, which exists in many pharmaceutical drugs and biologically active molecules [6] [7] .
From the multitude of contributions in the scientific literature, it is clear that AZT and 4-anilinoquinazolines can be considered as valuable compounds, both from a medicinal and a synthetic point of view. These findings have led to the hypothesis that hybridization of 4-anilinoquinazoline derivatives with AZT might result in the identification of useful anticancer hits for further elaboration. Moreover, AZT bears an azide functionality that could be conveniently exploited in its hybridization to other entities via 'click' chemistry. In addition, recent studies have revealed that triazole containing nucleosides exert a broad spectrum of pharmacological activities including antiviral [8] , and antitumor properties [9] [10] . Thus, in the present work, new triazolequinazoline-AZT hybrid compounds are targeted as potential cytotoxic agents by means of click chemistry-mediated fusion between AZT on the one hand and 4-anilinoquinazolines on the other hand. In light of the known biological properties of functionalized triazole, the introduction of a triazole linker in the premised 4-anilinoquinazoline-AZT conjugates might contribute to the overall activity of these hybrid systems as well. To this end, the hybridization between of AZT and N-(3-ethynylphenyl)quinazoline derivatives was first studied at anilino side chain of the quinazoline scaffold. Among numerous of bioactive quinazoline derivatives, erlotinib 1 is a well-known drug used to treat non-small lung cancer, pancreatic cancer and several other types of cancer [11] [12] . In this study, erlotinib was employed as a pharmacophoric template for synthesis of hybrid compound 2 following the synthetic procedure illustrated in Scheme 1. The 'click' reaction of AZT and erlotinib 1 was carried out in THF in the presence of CuI and N,Ndiisopropylethylamine (DIPEA) at room temperature for 3 days to furnish the target compound 2 in 85% yield. In order to provide a small library of novel quinazoline-triazole-AZT conjugates, the same procedure as explained above was applied to dioxygenated ring fused quinazolines 3a-c to obtain 4-anilino-quinazoline-triazole-AZT hybrids 4a-c in high yields (Scheme 2).
As a part of our going work, the hybridization of 4-anilinoquinazoline derivatives with AZT at C6-side chain of quinazoline scaffold is also studied. Compounds 5a-b, prepared by six-step methodology in our previous report [13] , were hybridized with 1.1 1634 Natural Product Communications Vol. 13 (12) 2018 Giang et al. The new prepared compounds were next subjected to in vitro biological assessment against three human cancer cell lines (KB, epidermoid carcinoma; HepG2, hepatoma carcinoma; SK-Lu-1, non-small lung cancer). Erlotinib hydrochloride, AZT, and ellipticine were used as positive controls. The biological results are summarized in Table 1 . As shown in Table 1 , in general, the synthesized compounds exhibited moderate cytotoxic inhibitory effects. It is important to note that the starting AZT display considerably less potent cytotoxic activities against KB and HepG2 cancer cell lines (IC 50 values > 400 µM) as compared to the most promising conjugates 4b and 6d showing a reasonable activity against these cancer cell lines. Especially, compounds 4b and 6d displayed up to 3-fold more potent than reference drugs erlotinib hydrochloride and AZT in term of anti-lung cancer activity.
In conclusion, the hybridization between AZT and 4-anilinoquinazoline derivatives was studied at anilino ring and at C6 side chain of quinazoline scaffold using 'click' chemistry techniques. The methods presented in this work allowed the synthesis of seven new 4-anilinoquinazoline-triazole-AZT hybrid compounds in high yields. All new synthesized hybrid compounds were assessed as anticancer agents in three human cancer cell lines (KB, HepG2, and Lu). The biological results indicated that compounds 4b and 6d displayed a promising potential for further elaboration toward novel anticancer agents.
Scheme 4:
Preparation of AZT-triazole-quinazoline hybrid 6d. Experimental General: Erlotinib, compounds 3a-c, and 5a-c were prepared by methodology in our previous reports [13] [14] . Other reagents were purchased as commercially available sources without further purification. Silica gel (60Å, particle size 40-60 µm) was used for column chromatography. Solvent systems were determined via initial TLC analysis on glass-backed silica plates (Merck Kieselgel 60 with F254 indicator, precoated 0.25 mm). High resolution 1 H NMR and 13 C NMR spectra were recorded on a Bruker Avance (500 MHz) using deuterated solvents and tetramethylsilane (TMS) as internal standard. Liquid chromatography -mass spectrometry analysis (LC-MS/MS) was recorded on a Q-Exactive focus instrument. HRMS was recorded on SCIEX X500 QTOF system. IR analysis was recorded on Spectrum Two Perkin Elmer. Melting points were measured using a Buchi Melting Point B-545 and are uncorrected.
General procedure for the synthesis of substituted 4-anilinoquinazoline-triazole-AZT hybrid compounds 2, 4a-c, 6a,b,d: To a respective solution of erlotinib 1 (1 mmol) or quinazoline derivatives 3a-c or 5a-c (1 mmol) in THF (10 ml) were added CuI (0.2 mmol) and N,N-diisopropylethylamine DIPEA (12 mmol) and the reaction mixture was stirred at room temperature for 10 min. Afterwards, AZT (1.1 mmol) was added, and the reaction mixture was stirred at room temperature until the reaction completed (1-5 days, checked by TLC). Upon completion, the resulting mixture was extracted with ethyl acetate (3 x 15 mL). The organic extracts were combined, then dried over Na 2 SO 4 
and evaporated in vacuo. The residue was purified by means of column chromatography to furnish pure target hybrid compounds 2, 4a-c, or 6a,b,d. 3-((6,7-bis(2-methoxyethoxy)quinazolin-4-yl)  amino)phenyl)-1H-1,2,3-triazol-1-yl)-5-(hydroxymethyl)-tetrahydrofuran-2-yl)-5-methylpyrimidine-2,4(1H,3H) 
1-((2R,4S,5S)-4-(4-(

1-((2R,4S,5S)-5-(hydroxymethyl)-4-(4-(3-(quinazolin-4-ylamino)phenyl)-1H-1,2,3-triazol-1-yl)tetrahydrofuran-2-yl)-5-methylpyrimidine-2,4(1H,3H)-dione (4a)
1-((2R,4S,5S)-4-(4-(3-([1,3]Dioxolo[4,5-g]quinazolin-8-yl amino)phenyl)-1H-1,2,3-triazol-1-yl)-5-(hydroxymethyl)tetrahydrofuran-2-yl)-5-methylpyrimidine-2,4(1H,3H)-dione (4b)
Colorless solid (Yield 87% 3-((7,8-dihydro-[1,4]dioxino[2,3-g]quinazolin-4-yl)amino)phenyl)-1H-1,2,3-triazol-1-yl) (1H, s, NH), 8.76 (1H, s), 8.51 (1H, s), 8.39 (1H, s), 8.14 (1H, s) , 7.91 (1H, d, J = 7 Hz), 7.84 (1H, s), 7.55 (1H, d, J = 6 Hz), 7.46 (1H, s), 7.22 (1H, s), 6.46 (1H, s), 5.43 (1H, s), 5.30 (1H, s), 4.41  (4H, s), 4.31 (1H, s), 3.74-3.70 (2H, m), 2.84-2.71 (2H, m) 4-((3-ethynylphenyl) Cell culture and cell viability assay: The synthesized compounds 2, 4a-c, and 6a,b,d were evaluated for their cytotoxicity against three human cancer cell lines, including epidermoid carcinoma cell line (KB), hepatoma carcinoma cell line (HepG2), and non-small lung cell line (SK-Lu-1). These cancer cell lines were obtained from the American Type Culture Collection (USA) ATCC. The cells were grown in RPMI 1640 medium supplemented with 10% fetal bovine serum, 100 U/mL penicillin, and 100 µg/mL streptomycin at 37°C in a humidified atmosphere (95% air and 5% CO 2 ). The exponentially growing cells were used throughout the experiments. The inhibitory effects of the compounds on the growth of the human cancer cell lines were determined by measuring the metabolic activity using a 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl-tetrazolium bromide (MTT) assay. Briefly, human cancer cell lines (3×10 4 cells/mL) were treated for 3 days with a series of concentrations of the compounds (in DMSO): 0.125, 0.5, 2.0, 8.0, 32.0, and 128.0 µg/mL. After incubation, 0.1 mg MTT solution (50 µL of a 2 mg/mL solution) was added to each well, and the cells were then incubated at 37°C for 4 h. The plates were centrifuged at 1000 rpm for 10 min at room temperature, and the media were then carefully aspirated. Dimethylsulfoxide (150 µL) was added to each well to dissolve the formazan crystals. The plates were read immediately at 540 nm on a microplate reader (TECAN GENIOUS). All the experiments were performed three times, and the mean absorbance values were calculated. The results are expressed as the percentage of inhibition that produced a reduction in the absorbance by the treatment of the compounds compared to the untreated controls. A dose-response curve was generated, and the inhibitory concentration of 50% (IC 50 ) was determined for each compound as well as each cell line.
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